Beta-blockers in cardiovascular diseases – Pros and Cons

Česká verzia

Authors: Vítovec J. ¹; Špinar J. ²; Špinarová L. ¹
Authors place of work: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně ¹; Lékařská fakulta MU Brno ²
Published in the journal: Kardiol Rev Int Med 2019, 21(2): 86-89

Summary

Beta-blockers are administered to treat a number of cardiovascular diseases – from arterial hypertension to heart failure. Recently, however, there have been a number of analyses and information that question the role of beta-blockers in some indications. We provide an overview of controversies associated with beta-blockers in the treatment of heart failure, hypertension, arrhythmia, secondary prevention of ischaemic heart disease and perioperative administration to patients with non-cardiac surgery.

Keywords:

SGLT2 – beta-blockers – hypertension – Arrhythmia – CAD – perioperative car

Zdroje

1. Vítovec J, Špinar J, Špinarová L et al. Farmakoterapie kardiovaskulárních onemocnění. 3. vyd. Praha: Grada Publishing 2017.

2. Vítovec J, Špinar J. Betablokátory v léčbě kardiovaskulárních onemocnění. Acta Med 2015; 8: 32–34.

3. Špinar J, Hradec J, Špinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Cor Vasa 2016; 58(5): e530–e568. doi: 10.1016/ j.crvasa.2016.09.004.

4. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H
et al. The BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344(22): 1659–1667. doi: 10.1056/ NEJM200105313442202.

5. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875–885. doi: 10.1016/ S0140-6736(10)61198-1.

6. Lund LH, Benson L, Dahlstrom U et al. Association between use of b-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 2014; 312(19): 2008–2018. doi: 10.1001/ jama.2014.15241.

7. Kotecha D, Holmes J, Krum H et al. Efficacy of b blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384(9961): 2235–2243. doi: 10.1016/ S0140-6736(14)61373-8.

8. Fauchier L, Laborie G, Clementy N et al. Beta-blockers or digoxin for atrial fibrillation and heart failure? Cardiac Fail Rev 2016; 2(1): 35–39. doi: 10.15420/ cfr.2015:28:2.

9. Allen LA, Fonarow GC, Simon DN et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol 2015; 65(25): 2691–2698. doi: 10.1016/ j.jacc.2015.04.045.

10. Kotecha D, Flather MD, Altman DG et al. Heart rate, heart rhythm, and prognostic benefits of beta-blockers in heart failure: individual patient-data meta-analysis. J Am Coll Cardiol 2017; 69(24): 2885–2896. doi: 10.1016/ j.jacc.2017.04.001.

11. Rienstra M, Damman K, Mulder BA et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013; 1(1): 21–28. doi: 10.1016/ j.jchf.2012.09.002.

12. Mordi IR, Santema BT, Kloosterman M et al. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clin Res Cardiol 2019. doi: 10.1007/ s00392-018-1409-x.

13. Vítovec J, Widimský J jr. Betablokátory. In: Widimský J. jr a spol. Hypertenze. 4. vyd. Praha: Triton 2014: 247–256.

14. Widimsky J jr, Filipovsky J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze & kardiovaskularni prevence 2018; 7 (Suppl): 3–20.

15. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of arterial hypertension? A meta-analysis. Lancet 2005; 366(9496): 1545–1553.

16. Hradec J. Kontroverze kolem betablokátorů. Vnitř Lék 2015; 61: 410–416.

17. Bangalore S, Makani H, Radford M et al. Clinical outcomes with b-blockers for myocardial infarction: a metanalysis od randomized trials. Am J Med 2014; 127(10): 939–953. doi: 10.1016/ j.amjmed.2014.05.032.

18. Kala P, Mates M, Želízko M et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Cor Vasa 2017; 59(6): e613–e644. doi: 10.1016/ j.crvasa.2017.10.008.

19. Bangalore S, Steg PG, Deedwania P et al. B-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308(13): 1340–1349. doi: 10.1001/ jama.2012.12
559.

20. Danchin N, Laurent S. Are beta blockers truly helpful in patients with CAD? Nat Rev Cardiol 2013; 10(1): 11–12. doi: 10.1038/ nrcardio.2012.159.

21. Steg PG, De Silva R. Beta-Blockers in asymptomatic coronary artery disease. No benefit or no evidence? J Am Col Cardiol 2014: 64(3): 253–255. doi: 10.1016/ j.jacc.2014.04.043.

22. Poldermans D, Bax JJ, Boersma E et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30(22): 2769–2812. doi: 10.1093/ eurheartj/ ehp337.

23. Devereaux PJ, Yang H, Yusuf S et al. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial). Lancet 2008; 371(9627): 1839–1847. doi: 10.1016/ S0140-6736(08)60601-7.

24. Kristensen SD, Knuuti J, Saraste A et al. 2014 ESC/ ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J 2014; 35(35): 2383–2431. doi: 10.1093/ eurheartj/ ehu282.

25. Friedell ML, Van Way CW 3rd, Freyberg RW et al. Beta-blockade and operative mortality in noncardiac surgery. Harmful or helpful? JAMA Surg 2015; 150(7): 658–663. doi: 10.1001/ jamasurg.2015.86